Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica M. Stempel, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Samuel Urrutia, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine McMahon, Rory M. Shallis, Joshua F. Zeidner, Hayley Hawkins, Michael R. Savona, Namrata Sonia Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L.
Blood Cancer Journal · Springer Nature · 2026-11-14 · DOI: 10.1038/s41408-026-01584-x

Abstract

Blood Cancer Journal, Published online: 14 November 2026; doi:10.1038/s41408-026-01584-x Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS

Read at publisher →

Similar articles